Roivant Sciences shares surge 5.78% intraday as stock hits all-time high of $23.47 amid analyst upgrades and drug development progress.

Roivant Sciences surged 5.78% intraday after hitting an all-time high of $23.47, driven by strong investor confidence in its strategic initiatives and drug development progress. The biopharmaceutical company’s shares rose 106.33% year-to-date and 95.07% in six months, reflecting optimism over accelerated timelines for brepocitinib in dermatomyositis (potential 2026 FDA submission) and non-infectious uveitis (Phase 3 enrollment complete). Analysts at Leerink Partners, H.C. Wainwright, and Guggenheim raised price targets to $32–$33 and reiterated "Strong Buy" ratings, citing reduced operational costs and higher projected profitability. The stock’s rally also aligns with its robust financial position (liquidity ratio of 33.7) and positive clinical milestones, reinforcing market expectations of long-term growth.